-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 26, CSPC Zhongqi Pharmaceutical's clinical application for SYHX2001 tablets submitted as a new drug category 1 was accepted by the CDE, and the product was declared for clinical use in China for the first time
.
According to data from Meinenet, since 2021, CSPC has submitted clinical applications for 14 Class 1 new drugs, and many have been approved for clinical use
Source: CDE official website
On October 26, the first class 1 new drug SYHX2001 tablet of CSPC Zhongqi Pharmaceutical was applied for clinical application for the first time
.
In addition to this product, CSPC (including subsidiaries, the same below) this month has 4 new drugs for clinical application, including Class 1 new drug recombinant anti-PD-1 fully human monoclonal antibody injection (not the first time), Class 2.
As a traditional Big Pharma in China, CSPC adheres to an innovative R&D strategy, increasing R&D investment year by year, and steadily advancing the product line under research
.
According to data from Minai.
Duensibu was approved by the FDA in September 2018.
From 2021 to the present, CSPC has applied for clinical Class 1 new drugs
Source: Meinenet MED2.
14 new class 1 drugs are concentrated in the field of anti-tumor therapy, including SYHA1402 tablets, recombinant fully human anti-RANKL monoclonal antibody injection, TG103 injection, recombinant anti-PD-1 fully human monoclonal antibody injection and other non-first clinical applications
